Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	419.37	225.27	104.86	71.43	348.61	71.79
Short-Term Investments	271.31	488.18	307.49	114.82	-	-
Cash & Short-Term Investments	690.68	713.45	412.35	186.24	348.61	71.79
Cash Growth	131.87%	73.02%	121.41%	-46.58%	385.59%	8.09%
Accounts Receivable	-	-	-	-	0.35	1.46
Other Receivables	-	-	-	0.85	5.77	15.7
Receivables	-	-	-	0.85	6.12	17.16
Prepaid Expenses	29.58	6.54	11.08	2.62	1.5	7.16
Restricted Cash	0.32	0.32	0.33	-	300	-
Other Current Assets	-	-	-	-	0.49	1.2
Total Current Assets	720.58	720.3	423.75	189.71	656.71	97.31
Property, Plant & Equipment	21.19	21.68	7.4	6.06	5.08	3.48
Goodwill	1.97	2	1.86	1.89	1.8	2.01
Other Intangible Assets	-	-	-	-	-	10.4
Other Long-Term Assets	8.45	7.21	2.55	5.28	0.58	0.17
Total Assets	752.19	751.18	435.56	202.95	664.17	113.37

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	22.9	20.29	4.64	2.67	0.36	4.37
Accrued Expenses	74.5	47.03	31.53	14.21	16.31	11.32
Current Portion of Long-Term Debt	-	-	-	-	19.77	-
Current Portion of Leases	3.55	3.39	3.77	2.81	1.69	1.09
Current Unearned Revenue	-	-	-	-	-	7.94
Other Current Liabilities	2.62	2.28	1.8	0.72	0.66	0.9
Total Current Liabilities	103.57	72.99	41.73	20.41	38.78	25.62
Long-Term Debt	-	-	-	100	494.54	-
Long-Term Leases	16.83	17.5	3.45	3.29	2.76	1.69
Other Long-Term Liabilities	1.8	1.83	1.63	1.56	1.43	2.78
Total Liabilities	122.2	92.32	46.81	125.26	537.51	30.09

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	7.93	7.75	7.38	7.02	2.11	0.98
Additional Paid-In Capital	3,324	2,948	1,598	1,066	504.77	384.05
Retained Earnings	-2,699	-2,294	-1,215	-993.26	-378.33	-299.55
Comprehensive Income & Other	-2.67	-2.54	-2.29	-2.45	-1.89	-2.2
Shareholders' Equity	629.98	658.86	388.75	77.69	126.65	83.28
Total Liabilities & Equity	752.19	751.18	435.56	202.95	664.17	113.37

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	20.38	20.89	7.22	106.1	518.76	2.78
Net Cash (Debt)	670.29	692.56	405.13	80.14	-170.16	69.01
Net Cash Growth	129.30%	70.95%	405.51%	-	-	4.63%
Net Cash Per Share	0.88	0.93	0.56	0.13	-0.88	0.75
Filing Date Shares Outstanding	797.75	775.37	737.68	701.7	697.69	98.12
Total Common Shares Outstanding	793.12	775.37	737.63	701.66	211.09	98.04
Working Capital	617.01	647.31	382.02	169.31	617.93	71.69
Book Value Per Share	0.79	0.85	0.53	0.11	0.60	0.85
Tangible Book Value	628.02	656.86	386.88	75.8	124.86	70.88
Tangible Book Value Per Share	0.79	0.85	0.52	0.11	0.59	0.72
Machinery	-	-	-	0.92	1.39	1.37
Leasehold Improvements	-	-	-	0.33	0.81	0.37

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Apr 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error